Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics

Dow Jones

16 Jan

By Connor Hart

Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading.

Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading.

Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer. Shares soar 66%, to $2.59, in postmarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 15, 2025 18:45 ET (23:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503601701"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503601701\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503601701?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 07:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503601701","market":"hk","top_or_hot":-1,"title":"Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading. \n</p>\n<p>\n  Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading. \n</p>\n<p>\n  Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer. Shares soar 66%, to $2.59, in postmarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2025 18:45 ET (23:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-16 07:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading. \n</p>\n<p>\n  Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading. \n</p>\n<p>\n  Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer. Shares soar 66%, to $2.59, in postmarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2025 18:45 ET (23:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4078","symbol_name":"消费电子产品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503601701","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503601701","pubTimestamp":1736984700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading.Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading.Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4078":"消费电子产品","BK4096":"电气部件与设备","BK4588":"碎股","PMAX":"Powell Max Limited","BK4112":"金融交易所和数据","GPRO":"GoPro","SER":"Serina Therapeutics, Inc.","LENZ":"Therapeutics","SLXN":"Silexion Therapeutics Corp","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"值得关注的股票：Serina Therapeutics、Powell Max、Silexion Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"US7Y.BOND":1,"US6M.BOND":1,"US5Y.BOND":1,"US3Y.BOND":1,"US30Y.BOND":1,"GPRO":1,"LENZ":1,"US2Y.BOND":1,"US12M.BOND":1,"US10Y.BOND":1,"SER":0.9,"SLXN":0.9,"PMAX":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading. \n\n\n  Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading. \n\n\n  Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer. Shares soar 66%, to $2.59, in postmarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2025 18:45 ET (23:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}